vimarsana.com

ஓஹியோ நிலை கல்லூரி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ibrutinib Effective for Severe Hairy Cell Leukemia

Ibrutinib Effective for Severe Hairy Cell Leukemia by Angela Mohan on  July 22, 2021 at 8:36 AM Blood. Hairy cell leukemia has generally a good prognosis for the majority of people affected. But, a small group of patients with variants of the disease do not respond well to existing U.S. Food and Drug Administration (FDA) approved therapies or cannot tolerate the side effects of established therapies. There is a critical unmet need for therapy options in this subset of patients to achieve long-term cancer control, said Dr. Kerry Rogers, principal investigator of the clinical trial and a hematologist/scientist at the OSUCCC - James.

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). Hairy cell leukemia is a rare form of B-cell blood cancer that is diagnosed in 600 to 800 people annually in the United States. Researchers note that while the disease generally has a good prognosis for the majority of people affected, a small group of patients with variants of the disease do not respond well to existing U.S. Food and Drug Administration (FDA) approved therapies or cannot tolerate the side effects of established therapies.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.